trending Market Intelligence /marketintelligence/en/news-insights/trending/cnvxl45ywo6z09yz17qyjq2 content esgSubNav
In This List

Sanofi gets German, US antitrust clearances for €3.9B Ablynx acquisition

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sanofi gets German, US antitrust clearances for €3.9B Ablynx acquisition

France's Sanofi secured U.S. and German antitrust clearances to acquire Belgian biotech Ablynx NV.

The drugmaker said the waiting period under the Hart-Scott-Rodino Act related to the deal has expired, which means the deal has gained U.S. antitrust clearance.

Germany's Federal Cartel Office also cleared the deal in accordance with the country's Act Against Restraints of Competition.

In January, Sanofi snatched Ablynx from rival Novo Nordisk A/S after offering to pay €3.9 billion, a significant premium to the target company's stock price. Ablynx had rebuffed Novo's offers as too low.

Sanofi plans to launch offers to buy all of Ablynx's ordinary shares, warrants and convertible bonds by the second quarter. The acquisition remains subject to other conditions, including the tender of about 75% of Ablynx's outstanding shares.

Just recently, Sanofi secured U.S. antitrust clearance for its $11.6 billion deal to acquire Waltham, Mass.-based hemophilia specialist Bioverativ Inc.